Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 144
- Registration Number
- NCT04091126
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT04061772
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Larysa Sanchez
- Target Recruit Count
- 18
- Registration Number
- NCT04052880
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients with Severe Autoimmune Encephalitis
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Jena University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03993262
- Locations
- 🇩🇪
Ludwig-Maximilians-Universität München, Klinikum Großhadern, München, Bayern, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachen, Germany
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 424
- Registration Number
- NCT03989414
- Locations
- 🇺🇸
Local Institution - 110, Winston-Salem, North Carolina, United States
🇨🇿Local Institution - 802, Brno, Czechia
🇨🇿Local Institution - 801, Ostrava-Poruba, Czechia
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03982771
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT03984097
- Locations
- 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 23
- Registration Number
- NCT03945591
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 49
- Registration Number
- NCT03942224
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.